Belite Bio, Inc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BLTE research report →
About the company
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease.
- CEO
- Yu-Hsin Lin
- IPO
- 2022
- Employees
- 25
- HQ
- San Diego, CA, US
Price Chart
- Market Cap
- $5.88B
- P/E
- -64.76
- P/S
- 0.00
- P/B
- 7.59
- EV/EBITDA
- -57.80
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -26.70%
- ROIC
- -13.15%
- Revenue
- $0 · 0.00%
- Net Income
- $-77,611,000 · -114.73%
- EPS
- $-2.31 · -95.76%
- Op Income
- $-84,208,000
- FCF YoY
- -26.48%
- 52W High
- $200.00
- 52W Low
- $57.99
- 50D MA
- $148.26
- 200D MA
- $142.06
- Beta
- -1.23
- Avg Volume
- 187.50K
Get TickerSpark's AI analysis on BLTE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 18, 26 | Scholl Hendrik Peter | sell | 96 |
| Jun 18, 26 | Scholl Hendrik Peter | sell | 3,748 |
| Jun 18, 26 | Scholl Hendrik Peter | sell | 4,861 |
| Jun 18, 26 | Scholl Hendrik Peter | sell | 1,199 |
| Jun 18, 26 | Scholl Hendrik Peter | sell | 96 |
| Jun 16, 26 | Scholl Hendrik Peter | sell | 2,054 |
| Jun 16, 26 | Scholl Hendrik Peter | sell | 784 |
| Jun 16, 26 | Scholl Hendrik Peter | sell | 3,140 |
| Jun 16, 26 | Scholl Hendrik Peter | sell | 540 |
| Jun 16, 26 | Scholl Hendrik Peter | sell | 100 |
Our BLTE coverage
Recent articles, reports, and earnings notes.
No research on BLTE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BLTE report →Similar companies
Peers in the same neighborhood.